RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to PelaJune 2021 paper - Transcriptome Signature of Immune Cells Post Reovirus Treatment in KRAS Mutated Colorectal Cancer
Reovirus propagates with high efficiency in KRAS mutated colorectal cancer (CRC). About 45–50% of CRC patients possess a KRAS mutation. Oncolytic reovirus treatment in combination with chemotherapy was tested in patients possessing KRAS mutated metastatic CRC.
MicroRNAs (miRNAs) consisting of small non-coding RNAs are utilized in post-transcriptional gene regulation, many of which are involved in T lymphocyte development, differentiation, and function.30 T cell activation and differentiation are dependent on the expression of multiple miRNAs with many mRNA targets.31 Our study has highlighted several genes within the miR in Lymphocytes gene pathway, which have shown significant alteration post-reovirus treatment.
[This is of significant interest to Big Pharma companies such as Roche and Pfizer, that are currently involved with the development of mRNA vaccines for the treatment of cancer.]
This is a valuable and informative study, with CRC patients receiving reovirus therapy. This study confirms that reovirus (commercially known as pelareorep) has a profound effect on gene expression in patients with KRAS mutated CRC. The conclusion state the findings strongly indicate that reovirus treatment leads to immune responses, which include increased lymphocytic maturation and activity, increased levels of apoptosis, and a decrease in angiogenesis
https://www.yu.edu/sites/default/files/inline-files/Avishai%20Samouha%20Reovirus%20Paper.pdf